United States: Capitol Hill Healthcare Update

Last Updated: September 13 2018
Article by Christian B. Jones

This week's "Capitol Hill Healthcare Update" includes the latest on a pending Senate vote on opioid legislation as Congress races to enact a response to the crisis before the November election; the Senate votes to expand Sunshine Act disclosure requirements; and a key House Republican backs requiring drug manufacturers to include prices in their ads; and more. (Note: Congress is in recess today and Tuesday in observance of Rosh Hashanah. The House and Senate will reconvene Wednesday for legislative business.)

This week's "Capitol Hill Healthcare Update" includes the latest on a pending Senate vote on opioid legislation as Congress races to enact a response to the crisis before the November election; the Senate votes to expand Sunshine Act disclosure requirements; and a key House Republican backs requiring drug manufacturers to include prices in their ads; and more. (Note: Congress is in recess today and Tuesday in observance of Rosh Hashanah. The House and Senate will reconvene Wednesday for legislative business.)

SENATE REACHES BIPARTISAN AGREEMENT ON OPIOIDS BILL

The Senate this week is scheduled to vote on legislation to address the opioid crisis after lawmakers reached a bipartisan agreement on a package of more than 70 individual proposals, including expanding access to medication-assisted treatment and funding to spur research on nonaddictive painkillers.

Senate HELP Committee Chairman Lamar Alexander, R-Tenn., negotiated the agreement, which includes legislation previously approved by five Senate committees. Senate leaders want to avoid an open amendment process on the Senate floor, which led to the behind-the-scenes work by Alexander that intensified during the last several weeks.

The Senate bill would give the U.S. Postal Service new tools to block mail delivery of fentanyl and other illicit drugs, expand telehealth coverage for treatment options and allow the FDA to require opioids to be prescribed in shorter-duration blister packs of three or seven days rather than 30-day supplies.

It also includes language by Judiciary Committee Chairman Chuck Grassley, R-Iowa, to expand Sunshine Act reporting to include payments by prescription drug and medical device manufacturers to nurse practitioners, physician assistants, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwives. Sen. Claire McCaskill, D-Mo., unsuccessfully sought to add patient groups to the Sunshine reporting requirement.

The House approved a separate opioid measure in June, including changes to Medicare and Medicaid reimbursement rules that would allow for coverage of inpatient drug rehab services and non-opioid pain management drugs. The Senate is expected to include the House language and its provisions as one bill, which could help speed passage as lawmakers race to finalize the legislation before Congress adjourns ahead of the November elections.

KEY HOUSE GOP LAWMAKER BACKS CALL FOR DRUG PRICES IN ADS

Rep. Michael Burgess, R-Texas, urged House appropriators last week to agree to Senate-approved language targeting $1 million for HHS to develop regulations that would require pharmaceutical manufacturers to include pricing information in consumer advertising.

Burgess is the chairman of the House Energy and Commerce Health Subcommittee. He signed a letter to House Appropriations Committee leaders with Rep. Gene Green, D-Texas, the ranking Democrat on the Health Subcommittee.

The funding is included in the Senate's version of the fiscal 2019 HHS funding bill. House and Senate leaders are trying to negotiate a final HHS bill paired with funding for the Pentagon before the end of the current fiscal year on Sept. 30.

HHS Secretary Alex Azar has touted the pricing idea for months, but so far, House Republicans have been silent on the issue. With Azar actively lobbying lawmakers for the provision and now receiving public backing from key Republicans like Burgess, the funding is likely to be included in the final bill.

PHARMACY GAG-CLAUSE BILL WINS SENATE OK, ADVANCES IN HOUSE

The Senate last week unanimously approved legislation that would permit pharmacists to tell patients that paying for certain prescription drugs with cash would be less expensive than using insurance.

The House Energy and Commerce health subcommittee approved by voice vote a separate version of the legislation, which would prohibit pharmacist "gag clauses" in contracts between pharmacies and pharmacy benefit managers.

Introduced by subcommittee member and former pharmacist Rep. Buddy Carter, R-Ga., the legislation would prohibit gag clauses in employer and individual health insurance plans, as well as in Medicare Advantage and Part D prescription drug plans. The Senate-passed bill would apply only to Medicare plans, but the Senate plans a separate vote this week to expand the ban to drug plans providing employee benefits and insurance exchange coverage.

HHS Secretary Alex Azar has called the clauses "unconscionable."

FACING DEADLINE THIS MONTH, LAWMAKERS SCRAMBLE ON BUDGET FOR HEALTH AGENCIES

With the deadline to pass fiscal 2019 appropriations bills three weeks away, congressional leaders are scrambling to approve nine spending bills in three separate legislative packages, including funding for HHS, FDA and other health agencies.

Any spending bill not approved by Oct. 1 would need to be added to a stopgap funding bill to avoid a partial government shutdown. Temporary spending measures likely would extend current-year funding levels and programs to December, when lawmakers will convene for a post-election session to try to finalize spending.

House and Senate negotiators are close to finishing a bill that would include funding for the veterans' health system, which is expected to be enacted this month. Other conference committees are working on spending packages that include funding for FDA and funding for HHS and its related healthcare agencies.

COMMITTEE LEADERS CALL ON CMS TO RELIEVE MEDICARE RED TAPE

Republican leaders on the House Ways and Means Committee fired off three letters to CMS last week urging the agency to relieve administrative and regulatory burdens for Medicare providers.

Written by committee Chairman Kevin Brady, R-Texas, and Health Subcommittee Chairman Peter Roskam, R-Ill., the letters said CMS Administrator Seema Verma could cut red tape for hospitals, post-acute care providers, and physicians and ancillary services.

The committee has held several hearings during a yearlong examination of regulatory burdens faced by providers.

Brady and Roskam urged CMS to reduce regulatory burdens for hospital conditions of participation, co-location of providers, skilled nursing facility consolidated billing, hospital-quality star ratings and hospice audits.

HOUSE TO VOTE ON SERIES OF HEALTH BILLS

The House on Wednesday is scheduled to vote on a series of bipartisan healthcare bills, including one on how Medicare administrative contractors make local reimbursement decisions.

The bills are being considered expedited rules that require two-third votes for approval — a procedure typically reserved for legislation that enjoys wide bipartisan support.

One bill by Reps. Lynn Jenkins, R-Kan., and Ron Kind, D-Wis., would provide transparency and consistency for providers by codifying requirements that Medicare administrative contractors must follow when making local coverage determinations. The transparency would include open meetings for stakeholders, timely feedback to public comments and a reconsideration process.

Also scheduled for floor votes is legislation by Reps. Erik Paulsen, R-Minn., and Kind to codify existing regulations that ensure certain Medicare beneficiaries have time to make decisions about their Medicare coverage. Another bill, by Reps. Peter Roskam, R-Ill., and Earl Blumenauer, D-Ore., would create a three-year pilot program to test the use of smart card technology in Medicare.

All three bills won approval last week in the House Ways and Means Committee.

The House is also scheduled to vote on legislation by Rep. Jackie Walorski, R-Ind., that would retroactively suspend the Affordable Care Act's employer mandate, change the definition of full-time employee under the mandate and push out until 2023 the implementation of the ACA's 40 percent tax on "Cadillac" health plans. The bill has drawn opposition from Democrats and isn't likely to be considered in the Senate.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions